Effect of bile acid sequestrants on glycaemic control: protocol for a systematic review with meta-analysis of randomised controlled trials

Morten Hansen; David Peick Sonne; Kristian Hallundbæk Mikkelsen; Lise Lotte Gluud; Tina Vilsbøll; Filip Krag Knop

doi:10.1136/bmjopen-2012-001803

Effect of bile acid sequestrants on glycaemic control: protocol for a systematic review with meta-analysis of randomised controlled trials

Morten Hansen, David Peick Sonne, Kristian Hallundbæk Mikkelsen, Lise Lotte Gluud, Tina Vilsbøll, Filip Krag Knop

7 Citationer (Scopus)

Abstract

In addition to the lipid-lowering effect of bile acid sequestrants (BASs), they also lower blood glucose and, therefore, could be beneficial in the treatment of patients with type 2 diabetes mellitus (T2DM). Three oral BASs are approved by the US Food and Drug Administration (FDA) for the treatment of hypercholesterolaemia: colestipol, cholestyramine and colesevelam. The BAS colestimide/colestilan is used in Japan. Colesevelam was recently approved by the FDA for the treatment of T2DM. We plan to provide a systematic review with meta-analysis of the glucose-lowering effect of BASs with the aim to evaluate their potential as glucose-lowering agents in patients with T2DM.

Originalsprog	Engelsk
Tidsskrift	BMJ Open
Vol/bind	2
Udgave nummer	6
DOI	https://doi.org/10.1136/bmjopen-2012-001803
Status	Udgivet - 2012

Adgang til dokumentet

10.1136/bmjopen-2012-001803

Citationsformater

@article{78b4f8fbdaa14ac29beba1d591c51c57,

title = "Effect of bile acid sequestrants on glycaemic control: protocol for a systematic review with meta-analysis of randomised controlled trials",

abstract = "In addition to the lipid-lowering effect of bile acid sequestrants (BASs), they also lower blood glucose and, therefore, could be beneficial in the treatment of patients with type 2 diabetes mellitus (T2DM). Three oral BASs are approved by the US Food and Drug Administration (FDA) for the treatment of hypercholesterolaemia: colestipol, cholestyramine and colesevelam. The BAS colestimide/colestilan is used in Japan. Colesevelam was recently approved by the FDA for the treatment of T2DM. We plan to provide a systematic review with meta-analysis of the glucose-lowering effect of BASs with the aim to evaluate their potential as glucose-lowering agents in patients with T2DM.",

author = "Morten Hansen and Sonne, {David Peick} and Mikkelsen, {Kristian Hallundb{\ae}k} and Gluud, {Lise Lotte} and Tina Vilsb{\o}ll and Knop, {Filip Krag}",

year = "2012",

doi = "10.1136/bmjopen-2012-001803",

language = "English",

volume = "2",

journal = "BMJ Open",

issn = "2044-6055",

publisher = "BMJ Publishing Group Ltd",

number = "6",

}

TY - JOUR

T1 - Effect of bile acid sequestrants on glycaemic control

T2 - protocol for a systematic review with meta-analysis of randomised controlled trials

AU - Hansen, Morten

AU - Sonne, David Peick

AU - Mikkelsen, Kristian Hallundbæk

AU - Gluud, Lise Lotte

AU - Vilsbøll, Tina

AU - Knop, Filip Krag

PY - 2012

Y1 - 2012

N2 - In addition to the lipid-lowering effect of bile acid sequestrants (BASs), they also lower blood glucose and, therefore, could be beneficial in the treatment of patients with type 2 diabetes mellitus (T2DM). Three oral BASs are approved by the US Food and Drug Administration (FDA) for the treatment of hypercholesterolaemia: colestipol, cholestyramine and colesevelam. The BAS colestimide/colestilan is used in Japan. Colesevelam was recently approved by the FDA for the treatment of T2DM. We plan to provide a systematic review with meta-analysis of the glucose-lowering effect of BASs with the aim to evaluate their potential as glucose-lowering agents in patients with T2DM.

AB - In addition to the lipid-lowering effect of bile acid sequestrants (BASs), they also lower blood glucose and, therefore, could be beneficial in the treatment of patients with type 2 diabetes mellitus (T2DM). Three oral BASs are approved by the US Food and Drug Administration (FDA) for the treatment of hypercholesterolaemia: colestipol, cholestyramine and colesevelam. The BAS colestimide/colestilan is used in Japan. Colesevelam was recently approved by the FDA for the treatment of T2DM. We plan to provide a systematic review with meta-analysis of the glucose-lowering effect of BASs with the aim to evaluate their potential as glucose-lowering agents in patients with T2DM.

U2 - 10.1136/bmjopen-2012-001803

DO - 10.1136/bmjopen-2012-001803

M3 - Review

C2 - 23148345

SN - 2044-6055

VL - 2

JO - BMJ Open

JF - BMJ Open

IS - 6

ER -

Effect of bile acid sequestrants on glycaemic control: protocol for a systematic review with meta-analysis of randomised controlled trials

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater